Literature DB >> 24703800

Endothelial function and cardiovascular events in chronic kidney disease.

Yoshihiro Hirata1, Seigo Sugiyama2, Eiichiro Yamamoto1, Yasushi Matsuzawa3, Eiichi Akiyama4, Hiroaki Kusaka1, Koichiro Fujisue1, Hirofumi Kurokawa1, Junichi Matsubara1, Koichi Sugamura1, Hirofumi Maeda1, Satomi Iwashita1, Hideaki Jinnouchi5, Kunihiko Matsui6, Hisao Ogawa1.   

Abstract

BACKGROUND: As patients with chronic kidney disease (CKD) are at high risk of developing coronary artery disease (CAD), it is important to stratify their cardiovascular risk. We investigated whether peripheral endothelial dysfunction is associated with the presence of CAD in patients with CKD and is a predictor of cardiovascular events.
METHODS: We enrolled 383 CKD patients with at least one coronary risk factor. Peripheral endothelial function was assessed by reactive hyperemia peripheral arterial tonometry index (RHI). The presence of CAD was determined by coronary angiography. Cardiovascular events were assessed during follow-up.
RESULTS: Ln-RHI was significantly lower in risk factor-matched CKD patients (n=323) than risk factor-matched non-CKD patients (n=323) (0.527 ± 0.192 vs. 0.580 ± 0.218, p=0.001). In CKD patients (n=383), Ln-RHI was significantly lower in CAD (0.499 ± 0.183, n=262) than non-CAD (0.582 ± 0.206, n=121) (p<0.001) patients. Multivariate logistic regression analysis identified Ln-RHI as an independent factor associated with the presence of CAD (p=0.001). During a mean follow-up period of 30 months, 90 cardiovascular events were recorded in CKD patients. Multivariate Cox hazard analysis identified low-Ln-RHI as an independent predictor of cardiovascular events (hazard ratio=2.70, 95% confidence interval=1.62-4.51, p<0.001). The predictive value of combined Ln-RHI and Framingham risk score (FRS) was evaluated by net reclassification index (NRI) and C-statistics, which showed significant improvement (NRI=22%, p<0.001) (C-statistics: FRS=0.49, FRS+Ln-RHI=0.62, p=0.005).
CONCLUSIONS: Endothelial function was significantly impaired in CKD patients and correlated with the presence of CAD. Severe endothelial dysfunction was an independent and incremental predictor of cardiovascular events in CKD.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular events; Chronic kidney disease; Cohort study; Coronary artery disease; Endothelial dysfunction

Mesh:

Year:  2014        PMID: 24703800     DOI: 10.1016/j.ijcard.2014.03.085

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  17 in total

1.  Short period of high-intensity inspiratory muscle training improves inspiratory muscle strength in patients with chronic kidney disease on hemodialysis: a randomized controlled trial.

Authors:  Thiago Dipp; Fabrício Edler Macagnan; Jociane Schardong; Rafael Oliveira Fernandes; Luisa Cioato Lemos; Rodrigo Della Méa Plentz
Journal:  Braz J Phys Ther       Date:  2019-05-06       Impact factor: 3.377

2.  Differential impact of peripheral endothelial dysfunction on subsequent cardiovascular events following percutaneous coronary intervention between chronic kidney disease (CKD) and non-CKD patients.

Authors:  Noriaki Tabata; Seiji Hokimoto; Tomonori Akasaka; Yuichiro Arima; Kenji Sakamoto; Eiichiro Yamamoto; Kenichi Tsujita; Yasuhiro Izumiya; Megumi Yamamuro; Sunao Kojima; Koichi Kaikita; Hisao Ogawa
Journal:  Heart Vessels       Date:  2015-07-12       Impact factor: 2.037

3.  Assessing the accuracy of the OMRON HEM-907XL oscillometric blood pressure measurement device in patients with nondialytic chronic kidney disease.

Authors:  Jordana B Cohen; Tiffany C Wong; Bruce S Alpert; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-01-12       Impact factor: 3.738

Review 4.  Endothelial function testing and cardiovascular disease: focus on peripheral arterial tonometry.

Authors:  Rosa Maria Bruno; Tommaso Gori; Lorenzo Ghiadoni
Journal:  Vasc Health Risk Manag       Date:  2014-09-26

5.  Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects.

Authors:  Arrigo F G Cicero; Martino Morbini; Angelo Parini; Riccardo Urso; Martina Rosticci; Elisa Grandi; Claudio Borghi
Journal:  Ther Clin Risk Manag       Date:  2016-02-23       Impact factor: 2.423

Review 6.  Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.

Authors:  Andreas B Gevaert; Katrien Lemmens; Christiaan J Vrints; Emeline M Van Craenenbroeck
Journal:  Oxid Med Cell Longev       Date:  2017-06-19       Impact factor: 6.543

7.  Reactive Hyperemia Index in Patients on Maintenance Hemodialysis: Cross-sectional Data from a Cohort Study.

Authors:  Wenjin Liu; Meijuan Meng; Jianping Chen; Liang Wang; Zhuxing Sun; Xiurong Li; Jianmei Zhou; Chaoqing Gao; Jiajun Zhou; Hong Chu; Wei Fan; Youwei Bai; Junwei Yang
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

8.  Altered vascular function in chronic kidney disease: evidence from passive leg movement.

Authors:  Elissa K Katulka; Alexandra E Hirt; Danielle L Kirkman; David G Edwards; Melissa A H Witman
Journal:  Physiol Rep       Date:  2019-04

9.  Impaired Peripheral Endothelial Function Assessed by Digital Reactive Hyperemia Peripheral Arterial Tonometry and Risk of In-Stent Restenosis.

Authors:  Naohiro Komura; Kenichi Tsujita; Kenshi Yamanaga; Kenji Sakamoto; Koichi Kaikita; Seiji Hokimoto; Satomi Iwashita; Takashi Miyazaki; Tomonori Akasaka; Yuichiro Arima; Eiichiro Yamamoto; Yasuhiro Izumiya; Megumi Yamamuro; Sunao Kojima; Shinji Tayama; Seigo Sugiyama; Kunihiko Matsui; Sunao Nakamura; Kiyoshi Hibi; Kazuo Kimura; Satoshi Umemura; Hisao Ogawa
Journal:  J Am Heart Assoc       Date:  2016-06-17       Impact factor: 5.501

Review 10.  Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity.

Authors:  Uwe Querfeld; Robert H Mak; Axel Radlach Pries
Journal:  Clin Sci (Lond)       Date:  2020-06-26       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.